South Korean (KOSPI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the South Korean Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 12 Jun 2026	₩73.8t	₩5.7t	₩1.5t	16.1x	50.1x	12.9x
Sun, 10 May 2026	₩85.6t	₩5.7t	₩1.5t	38.9x	55.3x	15x
Tue, 07 Apr 2026	₩88.6t	₩5.4t	₩1.4t	41.7x	62.5x	16.3x
Thu, 05 Mar 2026	₩85.1t	₩5.4t	₩1.5t	15.5x	56.2x	15.7x
Sat, 31 Jan 2026	₩99.6t	₩5.4t	₩1.5t	16.3x	65.8x	18.4x
Mon, 29 Dec 2025	₩94.3t	₩6.4t	₩1.5t	16.5x	63.1x	14.8x
Wed, 26 Nov 2025	₩92.6t	₩6.3t	₩1.5t	16.5x	61.1x	14.7x
Fri, 24 Oct 2025	₩96.6t	₩5.8t	₩1.2t	16.3x	81.5x	16.5x
Sun, 21 Sep 2025	₩88.0t	₩5.8t	₩1.2t	14.7x	74.2x	15.1x
Tue, 19 Aug 2025	₩88.6t	₩5.7t	₩1.2t	16.7x	72.3x	15.6x
Thu, 17 Jul 2025	₩86.4t	₩5.6t	₩1.2t	15.9x	70.3x	15.3x
Sat, 14 Jun 2025	₩83.2t	₩5.6t	₩1.2t	15.3x	67.5x	14.8x
Mon, 12 May 2025	₩83.8t	₩5.2t	₩1.0t	18.2x	81.8x	16.1x
Wed, 09 Apr 2025	₩79.8t	₩5.2t	₩1.0t	16.2x	77.5x	15.3x
Fri, 07 Mar 2025	₩89.1t	₩5.2t	₩996.4b	12.4x	89.4x	17.2x
Sun, 02 Feb 2025	₩86.3t	₩5.0t	₩965.6b	12.6x	89.4x	17.2x
Tue, 31 Dec 2024	₩75.9t	₩5.0t	₩965.6b	13x	78.6x	15.2x
Thu, 28 Nov 2024	₩75.2t	₩5.0t	₩908.5b	19.1x	82.7x	15x
Sat, 26 Oct 2024	₩84.7t	₩4.8t	₩885.3b	13.1x	95.6x	17.5x
Mon, 23 Sep 2024	₩83.2t	₩4.8t	₩885.3b	14.9x	93.9x	17.2x
Wed, 21 Aug 2024	₩71.6t	₩4.8t	₩863.7b	16.1x	82.8x	14.8x
Fri, 19 Jul 2024	₩67.1t	₩4.5t	₩731.7b	18.2x	91.8x	14.8x
Sun, 16 Jun 2024	₩58.1t	₩4.6t	₩691.8b	19.8x	84x	12.6x
Tue, 14 May 2024	₩61.2t	₩4.4t	₩635.1b	19.7x	96.4x	14x
Thu, 11 Apr 2024	₩63.7t	₩4.7t	₩654.7b	18.8x	97.2x	13.7x
Sat, 09 Mar 2024	₩66.4t	₩4.6t	₩635.2b	34.5x	104.6x	14.3x
Mon, 05 Feb 2024	₩66.7t	₩4.5t	₩714.4b	33.1x	93.3x	14.7x
Wed, 03 Jan 2024	₩62.8t	₩4.5t	₩721.5b	33.4x	87x	13.8x
Fri, 01 Dec 2023	₩57.2t	₩4.5t	₩726.0b	32.4x	78.8x	12.6x
Sun, 29 Oct 2023	₩56.4t	₩4.4t	₩660.9b	21.4x	85.4x	12.8x
Tue, 26 Sep 2023	₩55.1t	₩4.4t	₩660.9b	34x	83.4x	12.5x
Thu, 24 Aug 2023	₩60.1t	₩4.2t	₩672.8b	28.8x	89.3x	14.3x
Sat, 22 Jul 2023	₩58.7t	₩4.2t	₩673.4b	29.2x	87.2x	14x
Mon, 19 Jun 2023	₩60.3t	₩4.2t	₩666.5b	30.1x	90.4x	14.2x

Current Industry PE

Investors are pessimistic on the South Korean Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 50.1x which is lower than its 3-year average PE of 80.8x.

The 3-year average PS ratio of 15.1x is higher than the industry's current PS ratio of 12.9x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have grown 30% per year over the last three years.
Revenues for these companies have grown 10% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does South Korean Clinical Research and Equipment compare with similar industries?


KR Market	-11.94%
Healthcare	-7.85%
Life Sciences	-6.38%
Clinical Research and Equipment	-6.38%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Company	Last Price	7D	1Y	Valuation
A038290 Macrogen	₩12.94k	2.3% +₩3.1b	-18.7%	PE36.8x
A002630 ORIENT BIO	₩978.00	1.2% +₩711.4m	-48.7%	n/a
A215570 Cronex.Co.Ltd	₩899.00	1.1% +₩56.7m	51.1%	n/a

Company

Last Price

Valuation

A038290 Macrogen

₩12.94k

2.3%
+₩3.1b

-18.7%

PE36.8x

A002630 ORIENT BIO

₩978.00

1.2%
+₩711.4m

-48.7%

n/a

A215570 Cronex.Co.Ltd

₩899.00

1.1%
+₩56.7m

51.1%

n/a

Penetrium Bioscience Unveils Breakthrough Mechanism for Targeted Cancer Therapy

Penetrium Bioscience announced compelling new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism behind the long-standing "Seed & Soil" theory originally proposed by Stephen Paget in 1889. The findings reveal how pathological tumor microenvironments ("soil") fundamentally limit the efficacy of targeted therapies—and how Penetrium's novel approach overcomes this barrier. The data, presented ahead of the company's participation at AACR 2026, introduce a paradigm-shifting mechanism that directly addresses the long-standing challenge of sub-lethal drug exposure, a key driver of therapeutic resistance in oncology. Penetrium's mechanism directly targets this barrier. By modulating pathological macrophages and cancer-associated fibroblasts (CAFs), the therapy disrupts the tumor's protective ecosystem, enabling co-administered therapies to achieve full lethal concentrations at the tumor site. This approach not only enhances therapeutic efficacy but also prevents the emergence of adaptive resistance at its source. The findings were independently validated through collaborative studies conducted by Seoul National University Hospital and KAIST (Korea Advanced Institute of Science and Technology). These studies confirmed that Penetrium's observed effects in pathological models are fully consistent with prior RNA sequencing (RNA-seq) data derived from pancreatic cancer organoids. This alignment provides strong evidence that Penetrium's mechanism is not limited to a specific tumor type, but rather represents a broadly applicable platform for microenvironment normalization across multiple cancers. A critical implication of this research is the resolution of the "sub-lethal dose" dilemma—where insufficient drug exposure leads to incomplete tumor killing and subsequent resistance. By dismantling the tumor's physical and biological defense systems, Penetrium enables therapies to reach effective lethal concentrations, thereby: Eliminating the conditions that foster adaptive resistance; Enhancing the durability of existing targeted therapies; Potentially restoring efficacy to blockbuster drugs limited by resistance. The company is actively pursuing strategic collaborations with global biopharma partners to integrate Penetrium into combination therapy regimens across oncology indications. Penetrium Bioscience will present its full dataset and global clinical development roadmap at AACR 2026 Annual Meeting in San Diego, engaging with leading oncology experts and multinational pharmaceutical companies. The company aims to position Penetrium as a first-in-class microenvironment-normalizing platform capable of redefining therapeutic strategies across oncology and beyond.

South Korean (KOSPI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Less than half of directors are independent

New minor risk - Market cap size

We're Interested To See How LigaChem Biosciences (KOSDAQ:141080) Uses Its Cash Hoard To Grow

New minor risk - Market cap size

First quarter 2026 earnings released

Penetrium Bioscience Unveils Breakthrough Mechanism for Targeted Cancer Therapy

Full year 2025 earnings released: ₩1,203 loss per share (vs ₩1,337 loss in FY 2024)

Cronex.Co.,Ltd, Annual General Meeting, Mar 31, 2026

Peptron, Inc., Annual General Meeting, Mar 26, 2026

New minor risk - Share price stability

FutureChem Co.,Ltd, Annual General Meeting, Mar 26, 2026